% Expired Patents = 14.3

EPO Patents = 4

Forward Citations = 26

Loading Chart...

3 inventors (with patents filed for the assignee):

Nalan Utku (5 out of 10 patents)

Steven R Gullans (2 out of 10 patents)

Nalân Utku (2 out of 2 patents)

7 patents: Sort by Forward Citations

1. 11892454 - Method for the diagnosis of etoposide prodrug treatable cancer (2024-02-06),

2. 10183035 - Etoposide and prodrugs thereof for use in targeting cancer stem cells (2019-01-22),

3. 9889147 - Analogues of etoposide for the treatment of tumours (2018-02-13),

4. 9827261 - Etoposide and prodrugs thereof for use in targeting cancer stem cells (2017-11-28),

5. 9096654 - Peptides capable of modulating the function of TIRC7 (2015-08-04),

6. 8642512 - Method of detecting early immune activation (2014-02-04),

7. 7794715 - Anti-TIRC7 antibodies in therapy of inflammatory diseases (2010-09-14),

Cellact Pharma Gmbh is a leading pharmaceutical company specializing in the development and commercialization of innovative treatments for a wide range of diseases. With a strong focus on research and development, we strive to improve the lives of patients worldwide through cutting-edge therapies. Our dedicated team of experts is committed to delivering high-quality products and making a positive impact on global healthcare.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

7 Patents

#34 in Dortmund

#4,855 in Germany

Dortmund, Germany

Cellact Pharma Gmbh

Forward Citations = 26

3 inventors:

Nalan Utku (5 out of 10 patents)

Steven R Gullans (2 out of 10 patents)

Nalân Utku (2 out of 2 patents)

Please report any incorrect information to [email protected]

4 patents (EPO):

Please report any incorrect information to [email protected]